Found 81 clinical trials
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
Due to the limitations of COVID-19 treatment and in the absence of licensed antiviral for COVID-19, the historical choice of therapeutic convalescent plasma (CP) is considered especially against RNA viruses .It was known that convalescent plasma does not only neutralize the pathogens but provide passive immunomodulatory properties that allows the …
- 0 views
- 16 Feb, 2024
- 1 location
SBRT Dose Escalation for Reirradiation of Inoperable Lung Lesions
Prospective phase I study to evaluate the maximum tolerated dose (MTD) of SBRT for thoracic re-irradiation. Dose limiting toxicity will be pneumonitis G3. The potential advantage of the dose escalation planned in this study is the delivery of an ablative dose to radically treat patients with inoperable local relapse, without …
- 0 views
- 16 Feb, 2024
- 1 location
Based on the "Brain-gut -Lung" Axis the Mechanism of Treating Stroke-associated Pneumonia by Tong-Fu-Xing-Shen Capsules
The regulation of T cells / IL-17 pathway mediated by the intestinal flora has become a new molecular target for the treatment of SAP. To test whether TFXSCs are through the pathway as above, this protocol describes an ongoing randomized controlled clinical trial, based on the theory of traditional Chinese …
- 0 views
- 16 Feb, 2024
- 1 location
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and impaired oxygenation.
- 0 views
- 05 Aug, 2020
Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19
Brief Summary: The goal here is to evaluate dipyridamole in treating respiratory tract infection and circulatory dysfunction due to SARS-CoV-2 coronavirus in hospitalized CVID-19 patients. Infection with SARS-CoV-2 causes human COVID-19 (HCoV-19). The infection is associated with a deleterious inflammatory response and a prothrombotic state in addition to tissue damage …
- 0 views
- 16 Feb, 2024
- 1 location
Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth
This study seeks to assess the impact of physical and pulmonary rehabilitation on patients who have been diagnosed with COVID-19 in the short and long term in hopes of establishing a best practices protocol for treatment of future patients with this disease.
- 0 views
- 16 Feb, 2024
- 1 location
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
The trial evaluates the efficacy and safety of Tocilizumab, which rapidly reduces the inflammation process through inhibition of IL-6 in patients with moderate to severe COVID-19 with increased inflammatory markers. There will be two arms in the trial, one receiving the best supportive care, and the other receiving it plus …
- 0 views
- 05 Aug, 2020
Connexin Genotypes in Cystic Fibrosis
Gap junction proteins might be of importance for the influx of blood cells into the lung and may influence the course of pulmonary inflammation. Aims: To assess the relationship between gap junction proteins alpha 1 (GJA1/Connexin 43) and alpha 4 (GJA4/connexin 37) genotypes and clinical disease phenotype.
- 0 views
- 16 Feb, 2024
- 3 locations
Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients
This is a randomized controlled trial of isolated patients with diabetes admitted to Nordsjllands Hospital with or without COVID-19-pneumonia. A continuous glucose monitoring (CGM) based system with transmission of glucose data to a central system is used for remote monitoring of glucose levels and compared to standard finger-prick glucose.
- 0 views
- 16 Feb, 2024
- 1 location
A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19)
This is a randomized, double-blind, placebo-controlled, multicenter, 28-day study of adult participants hospitalized with COVID-19, with a safety follow-up telephone call at Day 60.
- 0 views
- 16 Feb, 2024
- 5 locations